≡

Recombinant Mitogen Activated Protein Kinase Kinase 1 (MAP2K1)

MAPKK1; MEK1; MKK1; PRKMK1; Dual specificity mitogen-activated protein kinase kinase 1; ERK activator kinase 1

  • Product No.RPD559Hu01
  • Organism SpeciesHomo sapiens (Human) Same name, Different species.
  • SourceProkaryotic expression
  • HostE.coli
  • Endotoxin Level<1.0EU per 1µg (determined by the LAL method)
  • Subcellular LocationMembrane, Cytoplasm
  • Predicted Molecular Mass38.8kDa
  • Accurate Molecular Mass38kDa(Analysis of differences refer to the manual)
  • Residues & TagsLeu54~Val369 with N-terminal His Tag
  • Buffer FormulationPBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
  • Traits Freeze-dried powder
  • Purity> 95%
  • Isoelectric Point7.0
  • Applications Positive Control; Immunogen; SDS-PAGE; WB.
    If bio-activity of the protein is needed, please check active protein.
  • DownloadInstruction Manual
  • UOM 10µg50µg 200µg 1mg 5mg
  • FOB US$ 184  US$ 460  US$ 920  US$ 2760  US$ 6900 
    For more details, please contact local distributors!

SEQUENCE

USAGE

Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

STORAGE

Avoid repeated freeze/thaw cycles. Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months.

STABILITY

The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
Graefe's Archive for Clinical and Experimental Ophthalmology Role of RhoA/MERK1/ERK1/2/iNOS signaling in ocular ischemic syndrome pubmed:27538909
PLOS ONE Identification of Biomarkers of Impaired Sensory Profiles among Autistic Patients. pubmed:27824861
Cancers Rationale for a Combination Therapy Consisting of MCL1-and MEK-Inhibitors in Acute Myeloid Leukemia Pubmed: 31718075
Cancers (Basel) BMI1-Inhibitor PTC596 in Combination with MCL1 Inhibitor S63845 or MEK Inhibitor Trametinib in the Treatment of Acute Leukemia. Cancers 2021, 13, 581 33540760
Catalog No. Related products for research use of Homo sapiens (Human) Organism species Applications (RESEARCH USE ONLY!)
RPD559Hu01 Recombinant Mitogen Activated Protein Kinase Kinase 1 (MAP2K1) Positive Control; Immunogen; SDS-PAGE; WB.
PAD559Hu01 Polyclonal Antibody to Mitogen Activated Protein Kinase Kinase 1 (MAP2K1) WB; IHC; ICC; IP.
MAD559Hu21 Monoclonal Antibody to Mitogen Activated Protein Kinase Kinase 1 (MAP2K1) WB; IHC; ICC; IP.
SED559Hu ELISA Kit for Mitogen Activated Protein Kinase Kinase 1 (MAP2K1) Enzyme-linked immunosorbent assay for Antigen Detection.
LMD559Hu Multiplex Assay Kit for Mitogen Activated Protein Kinase Kinase 1 (MAP2K1) ,etc. by FLIA (Flow Luminescence Immunoassay) FLIA Kit for Antigen Detection.